RevenueNet IncomeP/EP/SEBITDividendStocksMarket capitalizationDebtLiabilitiesEquityAAQSEmployeesROEROAROCE

Vifor Pharma ROE 2024

Vifor Pharma ROE

0.04

Vifor Pharma Dividend yield

1.2 %

Ticker

VIFN.SW

ISIN

CH0364749348

WKN

A2DRZ4

In 2024, Vifor Pharma's return on equity (ROE) was 0.04, a 0% increase from the 0 ROE in the previous year.

Vifor Pharma Aktienanalyse

What does Vifor Pharma do?

Vifor Pharma AG is a leading pharmaceutical company based in St. Gallen, Switzerland. The company has a long history and over 100 years of experience in the manufacturing of pharmaceutical products. It was founded in 1872 as Etablissements Gallois and has undergone various mergers and acquisitions. Today, it is part of the global Galenica Group and has branches in over 30 countries. Vifor Pharma AG focuses on the development and production of medications for the treatment of iron deficiency and kidney diseases. It diversifies its business across different market segments and geographic regions. The company's well-known products include iron preparations sold under different brands such as Ferinject, Injectafer, and Venofer, used for the treatment of iron deficiency anemia in both intravenous and tablet forms. another important business area for Vifor Pharma AG is nephrology, with a wide range of kidney and dialysis products available, including treatments for hyperphosphatemia and anemia in dialysis patients. To strengthen its innovation, the company has invested in partnerships, such as an exclusive license for the distribution of Vadadustat, an oral medication for the treatment of anemia in chronic kidney disease. Vifor Pharma AG has also invested in the digitalization and data-driven technologies, acquiring a stake in the Austrian company medisign GmbH in 2020 to expand its expertise in digital health and telemedicine. In terms of sustainability, the company aims to be carbon-neutral by 2025 and has implemented measures to reduce its CO2 footprint. With its long history, diverse portfolio of products and services, and investments in innovation and sustainability, Vifor Pharma AG is well-positioned for future success. Vifor Pharma ist eines der beliebtesten Unternehmen auf Eulerpool.com.

ROE Details

Decoding Vifor Pharma's Return on Equity (ROE)

Vifor Pharma's Return on Equity (ROE) is a fundamental metric evaluating the company's profitability relative to its equity. Calculated by dividing net income by shareholder's equity, ROE illustrates how effectively the company is generating profits from shareholders’ investments. A higher ROE represents enhanced efficiency and profitability.

Year-to-Year Comparison

Analyzing Vifor Pharma's ROE on a yearly basis aids in tracking its profitability trends and financial performance. An increasing ROE suggests enhanced profitability and value generation for shareholders, whereas a declining ROE may indicate issues in profit generation or equity management.

Impact on Investments

Vifor Pharma's ROE is instrumental for investors assessing the company's profitability, efficiency, and investment attractiveness. A robust ROE indicates the firm’s adeptness at converting equity investments into profits, thereby enhancing its appeal to potential and current investors.

Interpreting ROE Fluctuations

Changes in Vifor Pharma’s ROE can emanate from variations in net income, equity capital, or both. These fluctuations are scrutinized to evaluate management’s effectiveness, financial strategies, and the inherent risks and opportunities, aiding investors in making informed decisions.

Frequently Asked Questions about Vifor Pharma Stock

What is the ROE (Return on Equity) of Vifor Pharma this year?

The ROE of Vifor Pharma this year is 0.04 undefined.

How has the Return on Equity (ROE) of Vifor Pharma developed compared to the previous year?

The ROE of Vifor Pharma has increased by 0% decreased compared to the previous year.

What impact does a high ROE (Return on Equity) have on investors of Vifor Pharma?

A high ROE indicates that Vifor Pharma generates good returns on capital and is successful in monetizing its investments. This is a positive indicator for investors.

What impact does a low ROE (Return on Equity) have on investors of Vifor Pharma?

A low ROE can indicate that Vifor Pharma is having difficulties monetizing its investments successfully and can be a negative signal for investors.

How does a change in the ROE (Return on Equity) of Vifor Pharma affect the company?

A change in ROE (Return on Equity) of Vifor Pharma can be an indicator of the financial performance of the company and demonstrate how successful the company is compared to other companies in the same industry.

How to calculate the ROE (Return on Equity) of Vifor Pharma?

The ROE (Return on Equity) is calculated by dividing the company's profit by the total equity. The formula is: ROE = Profit / Total equity.

Which factors influence the ROE (Return on Equity) of Vifor Pharma?

Some factors that can influence Vifor Pharma's Return on Equity (ROE) include the efficiency in using equity, the profitability of the company, and the financing structure.

What strategic measures can take to improve the ROE (Return on Equity)?

To improve the Return on Equity (ROE), can take measures such as cost savings, increasing revenue, improving efficiency in the use of equity, and making changes in the financing structure. It is important for the company to conduct a thorough review of its financial situation to determine the best strategic actions to improve ROE.

How much dividend does Vifor Pharma pay?

Over the past 12 months, Vifor Pharma paid a dividend of 2 CHF . This corresponds to a dividend yield of about 1.2 %. For the coming 12 months, Vifor Pharma is expected to pay a dividend of 6.28 CHF.

What is the dividend yield of Vifor Pharma?

The current dividend yield of Vifor Pharma is 1.2 %.

When does Vifor Pharma pay dividends?

Vifor Pharma pays a quarterly dividend. This is distributed in the months of June, June, June, May.

How secure is the dividend of Vifor Pharma?

Vifor Pharma paid dividends every year for the past 24 years.

What is the dividend of Vifor Pharma?

For the upcoming 12 months, dividends amounting to 6.28 CHF are expected. This corresponds to a dividend yield of 3.78 %.

In which sector is Vifor Pharma located?

Vifor Pharma is assigned to the 'Health' sector.

Wann musste ich die Aktien von Vifor Pharma kaufen, um die vorherige Dividende zu erhalten?

To receive the latest dividend of Vifor Pharma from 5/3/2022 amounting to 2 CHF, you needed to have the stock in your portfolio before the ex-date on 4/29/2022.

When did Vifor Pharma pay the last dividend?

The last dividend was paid out on 5/3/2022.

What was the dividend of Vifor Pharma in the year 2023?

In the year 2023, Vifor Pharma distributed 2 CHF as dividends.

In which currency does Vifor Pharma pay out the dividend?

The dividends of Vifor Pharma are distributed in CHF.

Stock savings plans offer an attractive way for investors to build wealth over the long term. One of the main advantages is the so-called cost-average effect: by regularly investing a fixed amount in stocks or stock funds, you automatically buy more shares when prices are low, and fewer when they are high. This can lead to a more favorable average price per share over time. In addition, stock savings plans allow small investors access to expensive stocks, as they can participate with small amounts. Regular investment also promotes a disciplined investment strategy and helps to avoid emotional decisions, such as impulsive buying or selling. Furthermore, investors benefit from the potential appreciation of the stocks as well as from dividend distributions, which can be reinvested, enhancing the compounding effect and thus the growth of the invested capital.

Andere Kennzahlen von Vifor Pharma

Our stock analysis for Vifor Pharma Revenue stock includes important financial indicators such as revenue, profit, P/E ratio, P/S ratio, EBIT, as well as information on dividends. We also assess aspects such as stocks, market capitalization, debt, equity, and liabilities of Vifor Pharma Revenue. If you are looking for more detailed information on these topics, we offer comprehensive analyses on our subpages.